New Anticoagulants for Treatment of Venous Thromboembolism
- 1 March 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 28 (3), 380-386
- https://doi.org/10.1161/atvbaha.108.162677
Abstract
Anticoagulant therapy is the cornerstone of treatment of venous thromboembolism (VTE). Such treatment is divided into 2 stages: Rapid initial anticoagulation is given to minimize the risk of thrombus extension and fatal pulmonary embolism, whereas extended anticoagulation is aimed at preventing recurrent VTE, thereby reducing the risk of postphlebitic syndrome. With currently available drugs, immediate anticoagulation can only be achieved with parenteral agents, such as heparin, low-molecular-weight heparin, or fondaparinux. Extended treatment usually involves the administration of vitamin K antagonists, such as warfarin. Emerging anticoagulants have the potential to streamline VTE treatment. These agents include idraparinux, a long-acting synthetic pentasaccharide that is given subcutaneously on a once-weekly basis, and new oral anticoagulants that target thrombin or factor Xa. This article (1) reviews the pharmacology of these agents, (2) outlines their potential strengths and weaknesses, (3) describes ...Keywords
This publication has 29 references indexed in Scilit:
- Minimizing costs for treating deep vein thrombosis: the role for fondaparinuxJournal of Thrombosis and Thrombolysis, 2006
- Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary EmbolismChest, 2005
- Short- and long-acting synthetic pentasaccharides as antithrombotic agentsExpert Opinion on Investigational Drugs, 2005
- The Pharmacology and Management of the Vitamin K AntagonistsChest, 2004
- Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous ThrombosisAnnals of Internal Medicine, 2004
- Relationship Between Deep Venous Thrombosis and the Postthrombotic SyndromeArchives of Internal Medicine, 2004
- Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary EmbolismNew England Journal of Medicine, 2003
- Assessment of Outpatient Treatment of Deep-Vein Thrombosis With Low-Molecular-Weight HeparinArchives of Internal Medicine, 1998
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Mortality From Pulmonary Embolism in the United States: 1962 to 1984Chest, 1990